Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masahiro Nishibori

Showing results (1-10 of 235) with videos related to

Pageof 24
Sort By:
Journal of Pharmacological Sciences|January 19, 2005
Physiology and pathophysiology of proteinase-activated receptors (PARs): PrefaceMasahiro Nishibori
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 5, 2005
[Clinical importance and prospect of EBD/EBLM]Masahiro Nishibori
Rinsho Byori. the Japanese Journal of Clinical Pathology|March 26, 2003
[How to make the best use of the Internet]Masahiro Nishibori
Rinsho Byori. the Japanese Journal of Clinical Pathology|August 20, 2003
[What is the systematic review?]Masahiro Nishibori
Rinsho Byori. the Japanese Journal of Clinical Pathology|September 15, 2012
[Trends toward EBLM in the EBM era]Masahiro Nishibori
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|January 12, 2018
[HMGB1 as a representative DAMP and anti-HMGB1 antibody therapy]Masahiro Nishibori
Rinsho Byori. the Japanese Journal of Clinical Pathology|June 2, 2011
[Ethical issues]Masahiro Nishibori
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|March 4, 2014
[Discovery of drugs targeting HMGB1-RAGE system]Masahiro Nishibori, Hideo Takahashi
Rinsho Byori. the Japanese Journal of Clinical Pathology|November 4, 2015
[Utilization of Multi-Institutional Laboratory Data as an Evidence Database: The Current Status and Future Tasks--Chairmen's Introductory Remarks]Kazunori Miyake, Masahiro Nishibori
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 24, 2016
[Current status and future prospects in HMGB1 and receptor researches]Hideo Takahashi, Masahiro Nishibori
Pageof 24

Showing results (1-10 of 235) with videos related to

Sort By:
Pageof 24
Journal of Pharmacological Sciences|January 19, 2005
Physiology and pathophysiology of proteinase-activated receptors (PARs): PrefaceMasahiro Nishibori
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 5, 2005
[Clinical importance and prospect of EBD/EBLM]Masahiro Nishibori
Rinsho Byori. the Japanese Journal of Clinical Pathology|March 26, 2003
[How to make the best use of the Internet]Masahiro Nishibori
Rinsho Byori. the Japanese Journal of Clinical Pathology|August 20, 2003
[What is the systematic review?]Masahiro Nishibori
Rinsho Byori. the Japanese Journal of Clinical Pathology|September 15, 2012
[Trends toward EBLM in the EBM era]Masahiro Nishibori
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|January 12, 2018
[HMGB1 as a representative DAMP and anti-HMGB1 antibody therapy]Masahiro Nishibori
Rinsho Byori. the Japanese Journal of Clinical Pathology|June 2, 2011
[Ethical issues]Masahiro Nishibori
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|March 4, 2014
[Discovery of drugs targeting HMGB1-RAGE system]Masahiro Nishibori, Hideo Takahashi
Rinsho Byori. the Japanese Journal of Clinical Pathology|November 4, 2015
[Utilization of Multi-Institutional Laboratory Data as an Evidence Database: The Current Status and Future Tasks--Chairmen's Introductory Remarks]Kazunori Miyake, Masahiro Nishibori
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 24, 2016
[Current status and future prospects in HMGB1 and receptor researches]Hideo Takahashi, Masahiro Nishibori
Pageof 24